U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H21N3O2
Molecular Weight 311.3782
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of GSK-9089

SMILES

CCN(CC)C1=CC=C(\C=N\NC(=O)C2=CC=C(O)C=C2)C=C1

InChI

InChIKey=WLKOCYWYAWBGKY-CPNJWEJPSA-N
InChI=1S/C18H21N3O2/c1-3-21(4-2)16-9-5-14(6-10-16)13-19-20-18(23)15-7-11-17(22)12-8-15/h5-13,22H,3-4H2,1-2H3,(H,20,23)/b19-13+

HIDE SMILES / InChI

Molecular Formula C18H21N3O2
Molecular Weight 311.3782
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/15713377 | https://www.ncbi.nlm.nih.gov/pubmed/15713377 | https://www.ncbi.nlm.nih.gov/pubmed/17510420 | https://www.ncbi.nlm.nih.gov/pubmed/18071305

GSK-9089 (also known as DY131, N-(4-(Diethylaminobenzylidenyl)-N'-(4-hydroxy benzoyl)-hydrazine) is a novel selective agonist at estrogen-related receptors ERRβ and ERRγ, that displays minimal activity at ERRα, ERα and ERβ at concentrations up to 30 μM. DY131 inhibits growth in a diverse panel of prostate and breast cancer cell lines, causing cell death that involves the p38 stress kinase pathway and a bimodal cell cycle arrest.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Identification of an agonist ligand for estrogen-related receptors ERRbeta/gamma.
2005-03-01
Patents

Sample Use Guides

Bank vole were treated with 50 µg/kg bw; six doses every other day
Route of Administration: Intraperitoneal
MDA-MB-231 Cells were seeded into 3, 96-well plastic tissue culture dishes per line at 1,000 cells per well on day 0. On day 1, each plate was treated with DY131 (5 and 10 mkM) . Plates were re-dosed every 3 days and stained on days 3 or 4, 7 or 8, and 10 or 11. To stain, one plate per line was rinsed once with 1X Phosphate-Buffered Saline (PBS) and incubated with a solution of 0.5% w/v crystal violet (Sigma Aldrich) dissolved in 25% methanol: 75% water at 4°C for 10 minutes. Excess stain was removed and each plate was washed 5-6 times with deionized H2O and allowed to air dry completely. Stained cells were rehydrated in a 0.1M sodium citrate buffer dissolved in 50% ethanol: 50% water, then read on a plate reader at an absorbance of 550nm. Each experimental condition was performed in six replicate wells.
Substance Class Chemical
Created
by admin
on Mon Mar 31 22:51:23 GMT 2025
Edited
by admin
on Mon Mar 31 22:51:23 GMT 2025
Record UNII
5VWV92039E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DY-131
Preferred Name English
GSK-9089
Common Name English
BENZOIC ACID, 4-HYDROXY-, ((4-(DIETHYLAMINO)PHENYL)METHYLENE)HYDRAZIDE
Systematic Name English
BENZOIC ACID, P-HYDROXY-, (P-(DIETHYLAMINO)BENZYLIDENE)HYDRAZIDE
Systematic Name English
BENZOIC ACID, 4-HYDROXY-, 2-((4-(DIETHYLAMINO)PHENYL)METHYLENE)HYDRAZIDE
Systematic Name English
Code System Code Type Description
FDA UNII
5VWV92039E
Created by admin on Mon Mar 31 22:51:23 GMT 2025 , Edited by admin on Mon Mar 31 22:51:23 GMT 2025
PRIMARY
CAS
95167-41-2
Created by admin on Mon Mar 31 22:51:23 GMT 2025 , Edited by admin on Mon Mar 31 22:51:23 GMT 2025
PRIMARY
PUBCHEM
5497124
Created by admin on Mon Mar 31 22:51:23 GMT 2025 , Edited by admin on Mon Mar 31 22:51:23 GMT 2025
PRIMARY
Related Record Type Details
ACTIVE MOIETY